Skip to main content
. 2021 Oct 29;4:1235. doi: 10.1038/s42003-021-02741-7

Fig. 6. EC359 enhance the ability of HDACi to decrease the proliferation of patient-derived xenograft explants (PDE) ex vivo.

Fig. 6

a Schematic representation of ex vivo culture model. b TNBC PDX explants (UTPDX0001) were treated with EC359 (500 nM), vorinostat (10 µM), or combination for 72 h and the proliferation was determined using Ki67 immunostaining. Data are representative of three independent experiments (n = 3). c TNBC explants from three different PDX tumors (UTPDX0001, TM00096; TM00098) were treated with EC359 (500 nM), panobinostat (100 nM), romidepsin (50 nM) or combination for 72 h and the proliferation was determined using Ki67 immunostaining. Representative Ki67 staining from each treatment condition is shown. Data are representative of three independent experiments (n = 3). The number of Ki67-positive cells from five different images were counted and plotted as histogram. Error bars represent SD. In b, and c, p-values were calculated using one-way ANOVA.